



ICHOR Vascular Inc

To become the “1st line on the table therapy” in treating peripheral vascular occlusions by developing a “versatile” solution aimed at rapid reperfusion without the need for surgery or thrombolytic drug therapies.



Company Overview

ICHOR Vascular has developed a 7F (510k) arterial and a 14F venous percutaneous reperfusion system which offers versatility to treat a wide range of vascular occlusions (2mm – 18mm vessels) “A one size fits all system that replicates successful parameters of surgical clot removal. The technology gives physicians clinical flexibility and incorporates a health economic element that will make ICHOR a 1st line on the table therapy for physicians and hospitals.” The ICHOR System is addressing short-comings of current therapeutic options: Non-drug therapy Non-surgical therapy Avoids blood loss Avoids distal embolization Avoids scarring or valve damage Versatile to treat a wide range of Arterial & Venous occlusions Does not require capital equipment

Problem

Peripheral Vascular Occlusions are less studied or understood relative to Stroke or Coronary disease. Yet arterial and venous disease of the lower limbs is a larger, faster growing market with significant mortality rates. Tools and techniques have not improved outcomes in ~40 years yet costs are skyrocketing. Current options lack flexibility and broad utility!

Highlights

ICHOR Vascular Reperfusion System (7F arterial real world limited market release)
<https://evtoday.com/articles/2022-feb/the-ichor-reperfusion-system-for-clot-removal-in-lower-extremity-vascular-disease>

Go-To-Market Strategy

1. Finish the 7F and 14F developments (arterial and venous solutions). We have 7F 510(k) and the 14F is using the 7F as a predicate. We have conducted 25 patients to validate the bench and in vivo studies.
2. Limited Market Release with the 7F and 14F in early 2023 to perfect the messaging, validate the sales process, demonstrate repeat orders and ASPs, and begin the real-world clinical registry.
3. Series A to support the broader US sales expansion, EU market submissions, and OUS expansion opportunities.

What Makes Us Special

In a white-hot market with major players anxious to compete now

Financial Info

Raising
\$1.5M

Business Stage

Series A

Business Type

Healthcare

Meet the Team



Timothy Blair
CEO

- Top players all above \$5B market caps (\$20B global market)
- High Margin, High ASP, High Volume product lines
- Strategics all support “tools in toolbox” and seeking solutions

Devices that will 100% compete with Inari and Penumbra

- Proven mechanisms of action (50+ years)
- Versatility
- Economics

A US 510(k) cleared device (7F) used in 25+ patients

- Safety & Efficacy
- Excellent IP (granted, protected)

A platform into future indications

- Pulmonary Embolism
- Dialysis

Best in class team, advisors, and partners (therapeutic experts in R&D, Sales, Marketing, and Manufacturing)